JP2022548226A5 - - Google Patents
Info
- Publication number
- JP2022548226A5 JP2022548226A5 JP2022515885A JP2022515885A JP2022548226A5 JP 2022548226 A5 JP2022548226 A5 JP 2022548226A5 JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022548226 A5 JP2022548226 A5 JP 2022548226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- approximately
- concentration
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900060P | 2019-09-13 | 2019-09-13 | |
| US62/900,060 | 2019-09-13 | ||
| US202063044288P | 2020-06-25 | 2020-06-25 | |
| US63/044,288 | 2020-06-25 | ||
| PCT/US2020/050565 WO2021051003A1 (en) | 2019-09-13 | 2020-09-11 | Ophthalmic formulations of methotrexate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548226A JP2022548226A (ja) | 2022-11-17 |
| JP2022548226A5 true JP2022548226A5 (cg-RX-API-DMAC10.html) | 2023-09-20 |
| JP7682512B2 JP7682512B2 (ja) | 2025-05-26 |
Family
ID=74866765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515885A Active JP7682512B2 (ja) | 2019-09-13 | 2020-09-11 | メトトレキサートの眼科用製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US12616699B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4028015A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7682512B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220062617A (cg-RX-API-DMAC10.html) |
| CN (1) | CN114423432A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020344685A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3149467A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL291228A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021051003A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050101605A1 (en) | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| WO2005046746A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| MX2007003968A (es) | 2004-10-01 | 2008-03-04 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US20110200662A1 (en) | 2008-10-22 | 2011-08-18 | Arnold Glazier | Method For The Treatment Of Proliferative Disorders Of The Eye |
| CN105362221A (zh) | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US20140105956A1 (en) | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| CA2991921C (en) | 2014-07-30 | 2023-08-08 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| GB201522441D0 (en) * | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
| WO2018201146A1 (en) | 2017-04-28 | 2018-11-01 | Case Western Reserve University | Compounds and methods of treating retinal degeneration |
| CA3092828A1 (en) | 2018-03-01 | 2019-09-06 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress |
| WO2021051003A1 (en) | 2019-09-13 | 2021-03-18 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| US12678440B2 (en) | 2020-02-26 | 2026-07-14 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| WO2024129979A1 (en) | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
-
2020
- 2020-09-11 WO PCT/US2020/050565 patent/WO2021051003A1/en not_active Ceased
- 2020-09-11 EP EP20863798.3A patent/EP4028015A4/en active Pending
- 2020-09-11 CA CA3149467A patent/CA3149467A1/en active Pending
- 2020-09-11 US US17/753,721 patent/US12616699B2/en active Active
- 2020-09-11 KR KR1020227012402A patent/KR20220062617A/ko not_active Ceased
- 2020-09-11 JP JP2022515885A patent/JP7682512B2/ja active Active
- 2020-09-11 CN CN202080063801.6A patent/CN114423432A/zh active Pending
- 2020-09-11 AU AU2020344685A patent/AU2020344685A1/en not_active Abandoned
-
2022
- 2022-03-09 IL IL291228A patent/IL291228A/en unknown
- 2022-09-15 US US17/932,426 patent/US12005060B2/en active Active
- 2022-09-15 US US17/932,453 patent/US12005061B2/en active Active
-
2026
- 2026-04-09 US US19/643,612 patent/US20260224578A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682512B2 (ja) | メトトレキサートの眼科用製剤 | |
| JP6700348B2 (ja) | 持続型薬物送達インプラント | |
| ES2345018T3 (es) | Composiciones y procedimientos para tratar el segmento posterior del ojo. | |
| Gan et al. | Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial | |
| HK1231417A1 (zh) | 用於治疗眼科疾病和障碍的化合物 | |
| JP2010536797A5 (cg-RX-API-DMAC10.html) | ||
| JP2009535422A (ja) | 血管作動薬を含有する持続放出性眼内インプラント | |
| KR20070057698A (ko) | 이성 감염의 국소 치료 또는 예방을 위한 국소 이성 조성물및 방법 | |
| JP2012087151A (ja) | ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液 | |
| CN106999511A (zh) | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 | |
| JP2020536067A5 (cg-RX-API-DMAC10.html) | ||
| JP2021059554A (ja) | 増殖性硝子体網膜症用メトトレキサート | |
| JP2020117522A (ja) | 徐放性医薬組成物 | |
| CN107708738A (zh) | 含有柠檬酸酯的贮库制剂 | |
| RU2006124557A (ru) | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний | |
| JP2021152002A5 (cg-RX-API-DMAC10.html) | ||
| JP2024518558A5 (cg-RX-API-DMAC10.html) | ||
| JP2024516003A5 (cg-RX-API-DMAC10.html) | ||
| TW202519198A (zh) | 治療糖尿病黃斑水腫的方法 | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| Watanabe et al. | A Case of Corneal Endothelial Cell Loss After PreserFlo MicroShunt Implantation Requiring Device Removal and Ahmed Glaucoma Valve Implantation With Tube Insertion Into the Vitreous Cavity. | |
| Nahata et al. | Candida endophthalmitis associated with total parenteral nutrition | |
| Miserocchi et al. | Treatment of Intermediate Uveitis | |
| RU2025122399A (ru) | Способ лечения операционных осложнений при хирургическом лечении катаракты | |
| CN121925262A (zh) | 多黏菌素b/甲氧苄啶与利福平的增强型制剂及其眼部应用方法 |